GlassScriptPhysician profile
Kurt W Tauer
NPI 1053340802
$44,041.29
in general payments reported to CMS, 2019-2025
23 companies · $22K in 2025
The $22K reported for 2025 was more than what 89% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $82.29 · 2021: $68.95 · 2022: $35.84 · 2023: $113 · 2024: $9,034 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Travel and Lodging: $7,203 · Food and Beverage: $1,660 · Consulting Fee: $1,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,680.00 |
| Travel and Lodging | $7,203.18 |
| Food and Beverage | $1,659.65 |
| Consulting Fee | $1,437.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $40,192.73 | 2019-2025 | Keytruda |
| Eli Lilly and Company | $1,437.50 | 2025 | |
| Amgen INC. | $920.08 | 2019 | |
| Caris Mpi, INC. | $262.15 | 2025 | Mi Cancer Seek |
| Eisai INC. | $151.74 | 2019-2023 | |
| Lilly USA, LLC | $149.50 | 2019-2025 | Jaypirca, Verzenio |
| Daiichi Sankyo INC. | $131.10 | 2024-2025 | Enhertu, Datroway |
| Pfizer INC. | $120.60 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $104.47 | 2025 | Myrisk |
| Gilead Sciences, INC. | $91.63 | 2021-2025 | Trodelvy |
| Genzyme Corporation | $76.99 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $76.46 | 2023-2025 | Imfinzi, Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $58.78 | 2020-2024 | |
| Exelixis INC. | $55.46 | 2019-2024 | Cabometyx |
| Genentech USA, INC. | $46.34 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $41.71 | 2021-2025 | Optune Lua (Novottf-200t) |
| Emd Serono, INC. | $22.67 | 2024 | |
| Janssen Biotech, INC. | $20.68 | 2025 | Balversa, Akeega, Erleada |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.58 | 2019 | |
| Coherus Oncology, INC. | $17.08 | 2024 | |
| Teleflex LLC | $16.44 | 2022 | |
| Amag Pharmaceuticals, INC. | $13.83 | 2019 | |
| Agios Pharmaceuticals, INC. | $12.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurt Tauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.